Background. Kaposi sarcoma (KS) occurs mainly in immunocompromised patients and is strongly associated with infection with human herpesvirus 8 (HHV-8; also known as "KS-associated herpesvirus"). We hypothesized that KS is linked to deficiencie in specifi anti-HHV-8 T cell immunity.
sons with all forms of KS: HIV related, postengraftment, classic, and endemic [5] . Immunity seems to play a key role in the control of HHV-8 infection, because KS occurs mostly in immunocompromised patients, such as HIV-infected individuals, transplant recipients, and the elderly [6] . Furthermore, reports of clinical improvement in KS when immunity is restored [7, 8] suggest that immune cells play a curative role against HHV-8.
Specifi cytotoxic T lymphocytes (CTLs) are powerful antiviral agents that can be used in adoptive transfer therapies to cure EBV-induced tumors [9] . The development of such cellular immunotherapy for infection with HHV-8 requires a better understanding of CTL activity against this virus. The firs descriptions of HHV-8-specifi CTLs originated from studies that used cytotoxicity techniques and recombinant vaccinia viruses expressing HHV-8 proteins in either asymptomatic HHV-8 carriers or patients with HIV-related KS [10, 11] . To date, cytotoxicity [12] [13] [14] and interferon (IFN)-g enzyme-linked immunospot (ELISPOT) [15- 17] techniques have identifie only a few T cell epitopes. These studies found weak HHV-8-specifi T cell responses to these epitopes, but the small number of antigens tested may have biased the results. HHV-8-specifi T cell counts in HIV-infected patients appear to increase during immune reconstitution after the initiation of antiretroviral therapy [15, 18] . Nevertheless, the pathogenesis of HHV-8-related tumors remains unclear, especially the question of whether they result from a direct oncogenic effect of HHV-8, an indirect immune effect mediated by phagocytes or lymphocytes, or both.
Because KS occurs mainly in immunocompromised patients, we hypothesized that the clinical manifestations of HHV-8 infection are linked to deficiencie in specifi antiviral T cell immunity. We therefore studied HHV-8-specifi T cell responses in a large group of HHV-8-infected individuals in 2 different clinical situations: patients with KS (who either were coinfected with HIV or were HIV negative and had classic Mediterranean KS) and asymptomatic HHV-8 carriers who were coinfected with HIV. After choosing 3 proteins that are overexpressed in KS lesions (latent nuclear antigen 1 [LANA-1], K12, and K15) as principal targets of T cell responses, we detected HHV-8-specifi T cell responses by IFN-g ELISPOT assay, using 52 specifi synthetic peptides distributed on these proteins and 4 previously described HHV-8-specifi T cell epitopes.
SUBJECTS, MATERIALS, AND METHODS

Subjects.
The present study included 52 HHV-8-seropositive individuals (47 men and 5 women), who were classifie into 2 groups (table 1) . The firs group comprised HIV-coinfected asymptomatic HHV-8 carriers, who were divided into 2 subgroups: long-term nonprogressors (LTNPs;
) and pron p 15 gressors for HIV infection (hereafter, "HIV progressors"; ) (peripheral-blood mononuclear cell [PBMC] samples n p 8 were provided by the French ALT and IMMUNOCO study groups). The LTNPs were untreated, asymptomatic HIV-infected individuals (as define elsewhere [19] ), and the HIV progressors were receiving treatment for HIV infection. The second group comprised patients with KS, also divided in 2 subgroups: those who were coinfected with HIV ( ), and n p 12 those who were HIV negative and had classic Mediterranean KS (
). The HIV-related KS cases were classifie as stage n p 17 T1S1 ( ), T0S1 ( ), or T0S0 ( ) [20] ; the classic n p 3 n p 1 n p 8 KS cases were classifie as visceral ( ), disseminated cun p 1 taneous ( ), or locally indolent ( ). Table 1 sumn p 6 n p 10 marizes the ages, CD4 T cell counts, and HHV-8 and HIV loads in each group. Finally, 7 blood bank donors who were seronegative for HHV-8 (PBMC samples provided by E. Robinet, Etablissement Français du Sang, Besançon, France) were tested as a control group. HLA genotypes, which were available for 85% of the patients, were distributed similarly in all groups (in particular, the HLA-A2 genotype [for asymptomatic HHV-8 carriers, 12/22; for patients with KS, 10/22; and for blood donors, 2/7]. All subjects provided informed consent for participation in the study, which was conducted in accordance with the human-experimentation guidelines of Hôpital Pitié-Salpêtrière.
Synthetic peptides. The HHV-8 peptides synthesized (Epytop) were purifie to 180% by high-performance liquid chromatography: 4 previously described HHV-8 T cell epitopes on 3 lytic glycoproteins (table 2)-gpH 59-68 [13] , gp35/37 131-145 , gp35/37 211-225 [15] , and gpB 492-500 [16] -and 52 peptides on 3 viral proteins of interest, none of which have sequence similarity to EBV genes and most of which are expressed in KS lesions [21] . Specificall , 15mer peptides overlapping by 10 aa spanned the entire K12 sequence (containing the optimal K12 [17] [18] [19] [20] [21] [22] [23] [24] [25] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] TVFVAVHVPDVLLNG … K12 [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] VHVPDVLLNGWRWRL … K12 [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] VLLNGWRWRLGAIPP … K12 [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] WRWRLGAIPPLVCLL … K12 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] GAIPPLVCLLAISVV … K12 [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] LVCLLAISVVPPSGQ … K12 [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] AISVVPPSGQRGPVA … K12 41- LLNGWRWRL peptide described elsewhere [13, 15, 22] ) and the firs 3 exons of the K15 protein (predominant form) (table 2) [23] . Hydrophobicity prevented the synthesis of K15 [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] , K15 [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , and K15 [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] . Nine 9mer and 10mer peptides predicted to bind to HLA-A2 in LANA-1 [24] were synthesized, because protein length (1162 aa) precluded the synthesis of overlapping peptides. Previously described epitopes were tested individually by ELISPOT assay. K12, K15, and LANA-1 peptides were tested in pools of 5-11 peptides (K15 pool 4, 5 peptides; K12, 11 peptides) (table 2) . EBV peptides, including 20 EBV optimal peptides that ranged from 8mer to 11mer on Epstein-Barr nuclear antigen (EBNA)-3A, EBNA-3B, EBNA-3C, BMLF-1, latent membrane protein (LMP)-2, and BZLF-1 proteins (as described elsewhere [25] ) and that matched different HLA molecules, were tested in pools (table 2) .
IFN-g ELISPOT analysis.
Polyvinylidene difluoride-bot tomed 96-well plates (Millipore) were coated with capture antihuman IFN-g monoclonal antibody (MAb; Diaclone). After saturation, thawed PBMCs were added in duplicate or triplicate wells ( cells/well) and were incubated for 20 h at 37ЊC 5 1 ϫ 10 in 5% CO 2 with individual peptides at 5 mg/mL and with peptides in pools at a fina concentration of 2 mg/mL/peptide. Phytohemagglutinin-p (PHAp) (Murex) at a fina concentration of 0.5 mg/mL was used as a positive control, and medium 1 ϫ 10 with positive responses, and white symbols represent patients with negative responses. The HHV-8 IFN-g ELISPOT assay used 56 HHV-8-specific peptides: 4 previously identified peptides in gpB, gpH, and gp35/37; 9 optimal peptides predicted in latent nuclear antigen 1; 43 overlapping peptides covering K12; and exons 1-3 in K15. The nonparametric Mann-Whitney U test was used to compare groups with respect to the frequency of specific antiviral T cells. The EBV IFN-g ELISPOT assay used 20 EBV optimal peptides in Epstein-Barr nuclear antigen (EBNA)-3A, EBNA-3B, EBNA-3C, BMLF-1, latent membrane protein 2, and BZLF-1.
alone was used as a negative control. After washing, the second biotinylated anti-IFNg MAb (Diaclone) was added, followed by streptavidin-alkaline phosphatase conjugate (Amersham Biosciences) and then substrate. After drying, spots were counted using a dissection microscope. The number of peptide-specifi T cells, expressed as spot-forming cells per PBMCs, was 6 1 ϫ 10 calculated after the subtraction of negative control values. Results were considered to be positive when they exceeded 50 sfc/ PBMCs (i.e., the mean response of the blood donors 6 1 ϫ 10 plus 2 SD) and when responses to PHAp (the positive control) exceeded 2000 sfc/ PBMCs. 6 1 ϫ 10 CD8 T cell depletion. PBMCs were mixed with immunomagnetic beads specifi for CD8 (Dynal) for 1 h at 4ЊC in a 2-mL plastic tube for negative selection of PBMCs expressing CD8. The tube was then placed on a magnet for 5 min, trapping the bead-linked CD8-enriched T cells. The remaining T cells were used as effectors in IFN-g ELISPOT assays.
HHV-8 serological analysis and viral load. For HHV-8 serological analysis, antibodies against LANA-1 were detected by an indirect immunofluo escence assay [26] . Serum samples that were reactive at a 1:100 dilution were considered to be positive. PBMC DNA was extracted using the QIAamp system (QIAgen), was assayed using real-time polymerase chain reaction, and was quantifie using fluo escent TaqMan methods on an ABI Prism 7700 Sequence Detection System (PE Applied Biosystems). This combined the quantificatio of HHV-8 and albumin gene DNA, as described elsewhere [27] . HHV-8 load in PBMCs was expressed as the absolute number of HHV-8 genome copies/ human diploid cells, with a positive 5 1.5 ϫ 10 threshold of 10 copies/ PBMCs. 5 1.5 ϫ 10 T2 cell line HLA-A*0201 stabilization assay. HLA-A*0201 molecules may be stabilized and recognized by antibodies when antigen-processing-deficien T2 cells, which express low levels of this molecule on their surface and have impaired endogenous specifi presentation [28] , are coincubated with exogenous b2-microglobulin (b2M) and with peptides that are capable of binding to the relevant class I allele [29] . Aliquots of 5 5 ϫ 10 T2 cells were cultured overnight in supplemented RPMI 1640 and were incubated for 1 h with 1 mg of b2M (Sigma Aldrich) and with increasing concentrations of synthetic peptides (from 0.5 to 50 mg/mL). After washing, surface expression of class I HLA molecules was detected using a global HLA class I anti- Statistical analysis. Statistical analysis was performed using StatView software (version 5.0; SAS Institute). The nonparametric Mann-Whitney U test was used to compare groups with respect to CD4 T cell count, HHV-8 load, and HHV-8-specifi T cell count, and Spearman's nonparametric correlation test was used to examine potential correlations between HHV-8-specifi T cell count and either CD4 T cell count or HHV-8 load.
RESULTS
Characteristics of patients with KS and asymptomatic HHV-8 carriers.
We studied 52 HHV-8-infected individuals, including 29 patients who had received a diagnosis of KS (and either were HIV coinfected or were HIV negative and had classic Mediterranean KS) and 23 HIV-coinfected asymptomatic HHV-8 carriers who did not have KS. Negative control subjects were 7 HLA-matched HHV-8-seronegative blood donors. To match groups for CD4 T cell count, we separated patients into subgroups according to HIV and clinical status, distinguishing HIV-related KS ( ) from classic Mediterranean KS (n n p 12 p 17) in the KS group and LTNPs ( ) from HIV pron p 15 gressors ( ) in the group of asymptomatic HHV-8 carriers n p 8 (all of whom were coinfected with HIV). As table 1 shows, CD4 T cell counts did not differ significantl between the asymptomatic HHV-8 carriers and the KS group ( ), P p .54 between the LTNPs and the HIV-negative patients with classic KS ( ), or between the HIV progressors and the patients P p .49 with HIV-related KS ( ) (table 1) . HHV-8 loads were P p .93 also similar in the asymptomatic HHV-8 carriers and the patients with KS, both overall ( ) and for the CD4 T cell P p .93 count-matched subgroups (table 1) .
Lower magnitude of HHV-8-specifi T cell responses in patients with KS than in asymptomatic HHV-8 carriers. HHV-8-specifi T cell responses to the 3 proteins (LANA-1, K12, and K15) that are overexpressed in KS lesions [21] and that were selected as targets were detected by IFN-g ELISPOT assay. These assays used 9 optimal peptides predicted by a theoretical HLA-A2 binding score in LANA-1; forty-three 10-15mer overlapping peptides covering all of K12 and exons 1-3 in K15; and, finall , 4 previously identifie HHV-8 epitopes in gpB, gpH, and gp35/37 (table 2) 1 ϫ 10 P p .0004 difference was confi med when we compared the CD4 T cell count-matched subgroups: the higher CD4 T cell count group comprised the LTNPs and the HIV-uninfected patients with classic KS ( ), and the lower CD4 T cell count group P p .02 Similar magnitude of EBV-specifi T cell responses in patients with KS and in asymptomatic HHV-8 carriers. To assess the capacity of our patients to develop antiviral T cell responses, we simultaneously measured EBV-specifi T cell responses as a positive control, using an IFN-g ELISPOT assay with a set of 20 optimal peptides that matched different HLA alleles in the EBNA-3A, EBNA-3B, EBNA-3C, BMLF-1, LMP-2, and BZLF-1 proteins ( 1 ϫ 10 cell response. Overall, HHV-8-specifi T cell responses could be detected against the 3 latent viral proteins tested, with K12 being predominant. Four previously described T cell epitopes on HHV-8 gpH, gpB, and gp35/37 elicited responses in 7 subjects (6 asymptomatic HHV-8 carriers and 1 patient with KS), principally against gpH 59-68 ( responders), gpB 492-500 n p 4 ( responders), and gp35/37 211-225 ( responders). n p 5 n p 1 gpH 59-68 and gpB 492-500 have been reported to be HLA-A*0201 restricted [13, 16] , whereas no gp35/37 211-225 HLA restriction has been described [15] . Only 1 of 7 responders, however, had the HLA-A2 genotype. No patient responded to the gp35/ 37 131-145 peptide, which has been described as HLA-A24 restricted [15] . These results suggest that HHV-8-specifi T cells recognize both latent and lytic HHV-8 proteins and that pre- New human herpesvirus 8 (HHV-8)-specific T cell epitopes in latent nuclear antigen 1 (LANA-1), K12, and K15 1 ϫ 10 peared after CD8 T cell depletion in the single patient for whom PBMCs were still available (table 3). The 4 responders had HLA-B7 or HLA-B35 genotypes, suggesting that the K12 [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] peptide contains an optimal CD8 T cell epitope that may be presented by the HLA-B7 supertype. In 1 responder, the K12 46-60 peptide elicited IFN-g secretion (147 sfc/ PBMCs) that persisted 6 1 ϫ 10 after CD8 T cell depletion (107 sfc/ PBMCs) (table 3) . 6 1 ϫ 10 This findin suggests that this 15mer peptide is a CD4 T cell epitope.
Finally, we identifie 3 new immunogenic peptides in the K15 protein, which elicited responses in 3 asymptomatic HHV-8 carriers (figu e 3). The pool 3 15mer K15 peptides (aa 39-160) were tested separately in 1 responder (HIV progressor/ 212) to the pool who had available PBMCs. K15 121-135 was the only 15mer peptide to elicit a positive response (210 sfc/1 ϫ 10 6 PBMCs), as had the 9mer peptide K15 123-131 (predicted to bind to HLA-A2 [24] ) at a magnitude equivalent to that of the 15mer peptide (250 sfc/ PBMCs). The loss of re- 6 1 ϫ 10 sponse to K15 123-131 after CD8 T cell depletion indicates that the IFN-g-secreting T cells had a CD8 T cell phenotype (table  3) . In a T2 cell line HLA-A*0201 stabilization assay, this peptide bound significantl and in a concentration-dependent fashion to HLA-A2 molecules (figu e 4).
The pool 4 15mer K15 peptides (aa 151-185) were tested separately in 2 responders (LTNP/10001 and HIV progressor/ 212) to the pool who had available PBMCs. K15 151-165 was the only 15mer peptide to elicit a response in LTNP/10001 (183 sfc/ PBMCs) ( [30] , we verifie response specificit . An alignment search program [31] found that no HHV-8 epitopes from these proteins (gpH 59-68 , gpB 492-500 , LANA-1 238-246 , LANA-1 1116-1124 , and LANA-1 71-79 ) had 160% aa identity with the corresponding EBV proteins. Similarly, EBV BMLF-1 300-308 was not significantl identical (160%) to HHV-8 ORF57 (data not shown).
DISCUSSION
In the present study, T cell responses to HHV-8 were analyzed by an IFN-g ELISPOT assay that used 56 peptides in 6 proteins (K12, K15, LANA-1, and 3 glycoproteins). Because the control group of HHV-8-seronegative donors did not respond to the peptides and because these proteins have no sequence homologies with human or other herpesvirus proteins, we could verify that the responses detected were specifi for HHV-8.
We showed that patients with KS have significantl fewer HHV-8-specifi T cells than do asymptomatic HHV-8 carriers. This difference was not related to immune status, because it persisted between subgroups matched for CD4 T cell count and because we observed EBV-specifi responses of similar magnitudes in all patient groups. This evidence suggests that the lack of a response to HHV-8 is not associated with an alteration in global antiviral responses during age-related classic KS or HIV-related KS. Because K12, K15, and LANA-1 are overexpressed in KS lesions [32] , we know that the poor response in patients with KS is not due to a defect in their expression. In patients with active KS, the antigenic repertoire may shift toward other viral proteins, similar to the different repertoires in patients with active human cytomegalovirus (CMV) retinitis and in asymptomatic CMV carriers [33] . The latter shift, however, differs from that in patients with KS: it is not so great that some proteins do not elicit responses at all in one group. Finally, it is most unlikely that the absence of HHV-8 peptide recognition in the KS group can be attributed to nonmatching HLA genotypes, because the distribution of HLA alleles, especially of HLA-A2 ( and for the patients with n p 10 n p 12 KS and the asymptomatic HHV-8 carriers, respectively), was similar in both groups. HHV-8 loads were similar in both groups and were relatively low overall, although these loads are known to be higher in patients with KS than in asymptomatic HHV-8 carriers [34] . We might have observed higher HHV-8-specifi responses in patients with disseminated KS, because the extent of KS is correlated with HHV-8 load [35] . A recent study found a relationship between HHV-8-specifi T cell count and viral load in patients treated for active and probably disseminated HIV-related KS [36] . Like others [18] , however, we found no such correlation: of 6 patients with extended cutaneous or visceral KS and a detectable HHV-8 load, only 1 responded. The lack of HHV-8-specifi T cell responses in our patients with KS was, therefore, probably not related to their HHV-8 loads.
Another possibility is that HHV-8-specifi T cells are dysfunctional in KS and produce IFN-g poorly, as has been shown for other virus-specifi T cells [37] . We plan to use tetrameric HLA-peptide complexes to examine this hypothesis. Alternatively, HHV-8-specifi T cells may be located in KS lesions rather than in PBMCs, similar to how HCV-specifi T cells are located in the liver in chronic hepatitis [38] . In situ analysis was not feasible here but would be of interest, because KS lesions contain lymphocyte infiltrate [39] . Both hypotheses are compatible with the concept of a correlation between HHV-8-specifi T cell count and viral load and may also explain why we could not fin it by studying PBMCs with an ELISPOT assay. The relative weakness of HHV-8 responses compared with EBV responses in the KS group may be related to one of the many HHV-8 mechanisms of immune escape mediated by viral proteins expressed in KS as class I major histocompatibility complex modulation [40] .
HHV-8 epitopes previously reported to be HLA-A2 restricted [13, 16] induced responses in non-A2 patients. These data most probably resulted from HLA promiscuity [41] , and the gpH 59-68 and gpB 492-500 peptides may be presented by B7, because all 6 responders had the HLA-B7 supertype (data not shown). We also identifie 8 new HHV-8 immunogenic peptides. Three LANA-1 epitopes are 9mer A2 predicted peptides. We individualized a 15mer K12 [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] peptide that induced CD8 T cell responses in 5 patients, although we could not describe the optimal 9mer peptide by use of overlapping peptides (data not shown). Two 15mer peptides in K12 and K15 induced non-CD8 T cell responses, strongly suggestive of optimal CD4 T cell epitopes. Finally, although exhaustion of PBMC samples from responders prevented us from completely assessing the HLA restriction of the 9mer peptides K15 123-131 and K15 155-163 , we demonstrated that T cell responses for both peptides involved CD8 T cells and that K15 123-131 binds to the HLA-A2 molecule, thus suggesting that they are optimal CD8 T cell epitopes.
Our results demonstrate an association between both HIVrelated and classic KS and a lack of HHV-8-specifi T cell responses. This impairment may be responsible for the uncontrolled proliferation of HHV-8-transformed cells and the consequent occurrence of KS. Our study also identifie 8 new regions in 3 latent HHV-8 proteins (LANA-1, K12, and K15) that contain T cell epitopes, including, for the firs time, 2 CD4 T cell epitopes. These results substantially enlarge the pool of identifie T cell epitopes; contribute to the deciphering of cellular immunity to HHV-8, which remains poorly understood; and support further studies developing prophylactic or therapeutic immunotherapies against HHV-8-related tumors.
